Perspectives of New Therapies for Endometriosis

Jenny Valentina Garmendia, Jenny V Garmendia, Juan Bautista De Sanctis, Juan B De Sanctis
Recent patents on endocrine, metabolic & immune drug discovery · 2012 · vol. 6(3) , pp. 218–223 · doi:10.2174/187221412802481702 · PMID:22694252 · W2320565135
article OA: closed CC0 ⤵ 1 in-corpus citation
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This paper reviews new pharmacological approaches and patented therapies under development to treat endometriosis, an inflammatory disease impacting fertility.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-07, 2026-07-11 · read from full text ⓘ

This paper provides an overview of endometriosis as an inflammatory extra-uterine disease involving ectopic endometrial glandular epithelial and stromal cells, highlighting downstream effects on ovarian function, oocyte quality, embryo development and implantation, and uterine function, leading to infertility or spontaneous pregnancy loss. It notes that despite a global prevalence above 10%, an effective treatment has not yet been found, and it describes newly designed and patented pharmacological approaches intended as potential future therapies. The paper’s main limitation is that it is a perspective/overview rather than presenting results from original clinical or preclinical experiments. This paper is centrally about endometriosis — it surveys perspectives on new pharmacological therapies for endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis is an inflammatory disease characterized by the presence of endometrial glandular epithelial and stromal cells growing in the extra-uterine environment. The disease affects: ovarian function, oocyte quality, embryo development and implantation, and uterine function resulting in infertility or spontaneous pregnancy loss. Even though the world’s prevalence is above 10 %, an effective treatment has not yet been found. New pharmacological approaches have been designed and patented that could serve as future therapies for this disease. Keywords: Androgens, coagulation, endometriosis, fertility, GnHR, inflammation, progesterone, signal transduction.
Full text 677 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Endometriosis is an inflammatory disease characterized by the presence of endometrial glandular epithelial and stromal cells growing in the extra-uterine environment. The disease affects: ovarian function, oocyte quality, embryo development and implantation, and uterine function resulting in infertility or spontaneous pregnancy loss. Even though the world’s prevalence is above 10 %, an effective treatment has not yet been found. New pharmacological approaches have been designed and patented that could serve as future therapies for this disease.

Keywords

Androgens, coagulation, endometriosis, fertility, GnHR, inflammation, progesterone, signal transduction. 18

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisinfertility

MeSH descriptors

Drug Discovery Endometriosis Women's Health Drug Design Drug Discovery Endometriosis Female Humans Patents as Topic Women's Health

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (46)

Cited by (1)

Source provenance

europepmc
last seen: 2026-08-22T06:09:51.966504+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:16:11.197438+00:00
unpaywall
last seen: 2026-08-22T06:23:50.750314+00:00
License: CC0 · commercial use OK